Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant

Clinical trial NCT00088543 · COMPLETED

Trial details

NCT number: NCT00088543
Sponsor: Genzyme, a Sanofi Company
Status: COMPLETED
Phase: Not Applicable
Study type: INTERVENTIONAL

Acute Myelogenous Leukemia (AML)Acute Lymphocytic Leukemia (ALL)Graft vs. Host Disease (GvHD)

Start date: 2004-03-01
Primary completion: 2006-04-01
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.